Oregon Public Employees Retirement Fund grew its position in Illumina, Inc. (NASDAQ:ILMN) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,583 shares of the life sciences company’s stock after buying an additional 284 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Illumina were worth $3,104,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after purchasing an additional 255,498 shares in the last quarter. Capital World Investors lifted its position in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares in the last quarter. Winslow Capital Management LLC purchased a new stake in shares of Illumina in the second quarter worth approximately $211,584,000. Finally, HPM Partners LLC lifted its position in shares of Illumina by 29,103.8% in the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after purchasing an additional 749,424 shares in the last quarter. Institutional investors own 93.07% of the company’s stock.

ILMN has been the subject of a number of research analyst reports. Leerink Swann reissued an “outperform” rating and issued a $225.00 price target (up from $207.00) on shares of Illumina in a research report on Tuesday, September 12th. Piper Jaffray Companies reissued an “overweight” rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a research report on Monday, October 9th. Janney Montgomery Scott raised shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Citigroup Inc. increased their price target on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 25th. Finally, Bank of America Corporation increased their price target on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the stock. Illumina has a consensus rating of “Hold” and a consensus target price of $200.88.

In other Illumina news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total transaction of $29,827.95. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the sale, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. In the last 90 days, insiders sold 187,964 shares of company stock worth $38,454,069. 1.60% of the stock is currently owned by corporate insiders.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $208.94 on Friday. The stock has a market cap of $30,505.24, a price-to-earnings ratio of 61.09, a PEG ratio of 3.45 and a beta of 0.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the company posted $0.97 earnings per share. research analysts expect that Illumina, Inc. will post 3.75 EPS for the current year.

WARNING: “Illumina, Inc. (ILMN) Holdings Lifted by Oregon Public Employees Retirement Fund” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/11/12/illumina-inc-ilmn-holdings-lifted-by-oregon-public-employees-retirement-fund.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.